RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)

Back to opportunities

RFPNo Set aside used1

RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)view on SAM.gov

HEALTH AND HUMAN SERVICES, DEPARTMENT OF › BARDA - ASPR / DAAPPO / BARDA DCMA

Posted Jun 16, 2026

Due Jul 30, 2026

Washington, DC

NAICS 541714 – Research and Development in Biotechnology (except Nanobiotechnology)

Sol # 75A50126R00002

AI Summary

• BARDA seeks late-stage development and regulatory approval for 2-PAM autoinjectors to treat OP poisoning.
• Competition is unrestricted; no small business set-aside.
• Development encompasses adult and pediatric populations with a focus on nerve agents.
• Regulatory approval must be obtained within the contract period.

Description

BARDA seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.

Classification

NAICS541714

PSC CodeAB12

Place of Performance

CityWashington

StateDC

ZIP20024

CountryUNITED STATES

Contracting Office

OfficeBARDA - ASPR / DAAPPO / BARDA DCMA

CityWASHINGTON

StateDC

ZIP20515

Contacts

Erin Greninger, Contracting Officer

erin.greninger@hhs.gov

Greg Smith(secondary)

greg.smith1@hhs.gov

Attachments (1)

Attachment 1